

(19) (KR)  
(12) (A)

(51) . Int. Cl.7 (11) 10-2004-0099348  
C12P 41/00 (43) 2004 11 26

(21) 10-2004-7014868  
(22) 2004 09 21  
2004 09 21  
(86) PCT/US2003/008941 (87) WO 2003/083126  
(86) 2003 03 21 (87) 2003 10 09

(30) 60/366,767 2002 03 22 (US)

(71) 48674 1790

(72) , , .  
92024 818

, , .  
48642 4608

, , .  
48642 5001

111

, 48642 3919

(74)

(54) ( )

, 가 ( ) ; 가 , 가 ;  
가 . , 가 ( ) ;  
가 , 가 ;



가 .  
 ± ) - 1 - - 2 -  
 가  
 781-4790). ( *Candida antarctica* )  
 가  
 (S)-  
 1 - - 2 - (20 mmol  
 . 2.7% (w/v) ( ± ) - 1 - - 2 -  
 98% ee 20% (R)- 1 - - 2 -  
 (Baumann et al. (2000) Tetrahedron: Asymmetry 11:4781-4790).  
 CAL-B (Novozyme 435)  
 e ( 6,239,316 B1; EPO 99115154.9).  
 (R)-  
 ( ,  
 . 3  
 (R)- (S)- 1 - - 2 -  
 JP 1991-262377, JP 1991-262378 JP 1991-262379);  
 (Yanase et al. (1993) Biosci. Biotech. Biochem. 57:1334-1337).  
 가 CAL-B , 1 - - 2 -  
 hedron: Asymmetry 7:3181-3186). 1 - - 2 - 2 -  
 (Anthonsen et al. (1995) Tetrahedron: Asymmetry 6:3015-3022; Hoff et al. (1996) Tetrahedron:  
 Asymmetry 7:3187-3192). 1 - - 2 - ( 3% w/v)  
 (PLE) (Gais et al. (2001) J. Org.  
 Chem. 66:3384-3396).

, 가 ( )  
n- , , , ,  
t- , , , ,  
가 .  
,

B' CALB CAL-B

U

ee

E

' ( 1 - - 2 - ) PM

' ( 1 - - 2 - ) PMA

' (1 - -2 - ) PE

' (1 - -2- ) PEA

$$n - \quad ' (1 - n - \quad -2 - \quad ) \quad PnP$$

$$n - \quad \quad \quad ' (1 - n - \quad \quad \quad - 2 - \quad \quad \quad ) \quad PnPA$$

' (1 - - 2 - ) PiP

' (1 - -2- ) PiPA

$$n - \quad ' (1 - n - \quad - 2 - ) \quad PnB$$

tert-                  ' (1-tert-                  -2-                  )    PtB

' (1- -2- ) PPh

' (1- -2- ) PPhA

'P-  
, PM, PE, PnP, PiP, PnB, PtB PPh ( )

BA PPhA ( ) , C 2 , 'P- , PMA, PEA, PnPA, PiPA, PnBA, Pt '2-

( ) ' PGAE

( ) PGAEA

(*l*) *l*-PGAE

EtCA  
 EtFA  
 IPA  
 VA  
 EMA  
 '2,2,2-'  
 TfEB  
 DK  
 VP  
 3,6- - 1,4- - 2,5-  
 'v/v' / ( )

( ) 가 ( )  
 ( )  
 가 , ,

'R' 'S' ( ) , ,  
 , ,  
 '(+) (-)' ( + ) 가 ( ) , (-)  
 ( + ) 50:50 ( - )  
 R) (S) ( , ( + ) ( - ); ( )

'ee'  
 F (-) (+) - ( - ) - 100 x \*F (+) - F (-) \* = 1).  
 % ee)

F (+) \*F (+) - F (-) \* ee ee ( )

( ) , ( ) , ( ) 가 ( )

ee  
가 20% ( 10% , 5% )  
R- 30% ) 가 S- 20% ( 10% ( , S- ( , R- ) )  
'E'  
1 E 가 , 20 , E  
가 , 가

E 가 : (ee<sub>s</sub>), (ee<sub>p</sub>)  
 (c) 가 , 가 (Hydrolases in Organic Synthesis, Bornscheuer, UT and Kazlauskas, RJ (1999) Wiley - VCH, New York, section 3.1.1; and Chen et al., J. Am. Chem. Soc. 104: 7294-7299 (1982)).

$$E = \ln [1 - c(1 + ee_p)] / \ln [1 - c(1 - ee_p)]$$

$$E = \ln [(1-c)(1-ee_s)]/\ln [(1-c)(1+ee_s)]$$

$$E = \ln \{(1 - ee_s) / [1 + (ee_s / ee_p)]\} / \ln \{(1 + ee_s) / [1 + (ee_s / ee_p)]\}$$

, , , , CAL-B ( ), 가  
 (PEA), (PnPA), (PMA), (EA), ( )  
 (BA) (EPA) n- (PnPA), (EA), ( )  
 ( ) S- ( ) 1- ( ) ,  
 ( ), ( ) ( ) ( ) ( ) ( ) ,  
 (BA), (EPA), (EtA), (EtCA), (EMA)  
 (EtFA), (IPA), (VA), (VP), PMA PnPA  
 (TfEB), (DK), ( ), 2,2,2-

(%)

( , PGAE ) ( , PGAEA P  
GAE) 가

가 , 가

1 ( , )

0 100%


27  
)  
3%  
).

3% ),


가

가

가



, R



, R  
 $\text{CH}_3)_3\text{C}_6\text{H}_5$  II R  
 $\text{CH}_3, \text{CH}_3\text{CH}_2, \text{CH}_3(\text{CH}_2)_2, \text{CH}_3(\text{CH}_2)_3, \text{CH}(\text{CH}_3)_2, \text{C}($   
 $, 2,2,2-$  , 2,2,2- , , ,  
 $, 1-$  , , ,  
 $n-$  1- -2- (PMA), (PEA),  
 $(\text{EPA})$  (PnPA), 가 (EA), (BA)  
 $,$  가 , ,  
 $,$  B, LP'S', 가  
 $,$  ,  
 $(\text{PLE})$  B 100% v/v  
 $,$  50% 가 50% 가  
 $70\% \text{ ee}$  30% ,  
 $,$  R- R- S-

b) (a) (1, 2, 30, 70%; (c) 1, 2, : (d) ||, (>, >90% ee); (



(d) ( )

;

(e) 5-15 %,

5-10 %  
(b)

(R)-1,2-


(c) (S)-1,2-

(R)-1- p-  
-2-


(f) ( , R S

III

(e) (R)-1,2-



&lt; II&gt;



, R

II R C(CH<sub>3</sub>)<sub>3</sub>, C(CH<sub>3</sub>)<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, CH<sub>2</sub>CH=CH<sub>2</sub>, CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, C<sub>6</sub>H<sub>5</sub>(C<sub>6</sub>H<sub>5</sub>)<sub>2</sub>, C(C<sub>6</sub>H<sub>5</sub>)<sub>3</sub>, OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>

2,2,2-

, 2,2,2-

, 1-

, ,

1 - 2 -

(PnPA),

(PMA),

(EA),

(PEA),

(EPA)<sup>n</sup>

가

(BA)

가

B,

LP'S',

가

TSA), DOWEX DR-2030

, DOWEX MSC-1H+

DOWEX

40

130

80

100

50%

가

)

(

100%

(Larsson, A.L.E. et al. 1997. Angew. Chem., Int Ed. Engl. 36:1211-1212; Kim, M.-J. et al. 2001. J. Org. Chem. 66:4736-4738), (Pearson, B.A. et al. 1999. J. Org. Chem. 64:5237-5249) (Huerta, F.F. et al. 2000. Org. Lett. 2: 1037-1040)

, 6% (w/v) 1 - 2 -

CAL-B

88%

(Persson et al. 1999. J. Am. Chem. Soc. 121:1645-1650); R-1 - 2 -

4 -

&gt;99% % ee


)

(

가

1	( )				
2	GC/FID , pH 7.2) PM, 2.81 ; PMA-S, 4.10 ; PMA-R, 4.24	CAL-B (1.0 mg/Mℓ L-2 lyo.)	(S)-PMA 25% (v/v) PMA		( )
3	(S)-PMA L-2 lyo. mg/Mℓ ( )	CAL-B 0.1 mg/Mℓ ( )		PMA 25% (v/v) ( ), 1.0 mg/Mℓ ( )	2.0
4	-2- (%)	, L-2, c.-f., C2 (PPh) 35%	가 (a) (±)-1- (R)-PM PM/VA (75:25, % v/v)	-2- (R)-PPhA PPh/VA (80:20, % v/v) , L-2, c.-f., C2 (mg/Mℓ)	(PM) (%) ee (b) (±)-1- (% ee) 30% (v/v) PPh 70% (v/v)
5	CAL-B (1 mg/Mℓ)				
6	PEA 가 24		PEA ; (% ee 3 (48 ))	CAL-B 3가 8 13 (60 )	
7	PEA 가 2 CAL-B 0%)	9 가 ,	PEA ; (% ee 3 (48 ))	PEA 1.5 l , PEA 20% v/v ;	( )
8	32 -PE 1.5 l	(% ee ), PEA 20% v/v	PEA 가 (% ee CAL-B )	가 ,	(S)-PEA (R) ( 7 )
					( )
					( )
					( )

&lt; |&gt;





A (CAL-A) 가 (1-5 (CRL)). 가 (PSL),

CAL-B  
)  
,  
(S)-  
(R)-  
PE, PnP, PiP, PnB, PtB PPh  
가  
가

, 2가 , ( ) 가 ,  
 ) 가 . , 가 , 2가 .

가 CAL-B  
R , S 가  
가 R-  
R-

가 CAL-B  
R 가 ( )  
S 가 ( )  
R- ( )  
( )

, 가 ( )  
 ) 가 ( )

B (CAL-B) . 가 , ( ) 가

가 ) , ( ), ( )

B (CAL-B) . ,

가 , , , (GC)  
가 . ( 1 ),

50% ( ) , 가 100%

B (CAL-B) (Patkar et al. (1993) Ind J. Chem. Sect. B 32B: 76-80)  
 ( , NOVO Nordisk SP 52  
 5; Roche Molecular Biochemicals CHIRAZYME.RTM.L-2.Iyo)  
 . CAL-B , 가 ( , Nov  
 o Nordisk NOVOZYM.RTM.435; Roche L-2, c.-f., lyo, ( 1); Roche  
 L-2, c.f., C2 ( 2)) ,  
 ; .  
 .  
 .

CAL-B . , 가 ( , CAL-B )  
CAL-B , ,

가

, 가 ( ( 3-5 ), 가 . 가 , . 가 )



가 . 30% 50% ,  
80% ee , 90% ee , 95% ee

50% . ,

( ) ( ) 가 가

Mel, CAL-B 0.1 mg (1 g), CAL-B 1 mg ) CAL-B  
 2.5 mg 200 mg . , , 0.5 g  
 ( , ) , ,

) , [(Kim, K.-W., et al. 2001. Biocatalysis in ionic liquids: markedly enhanced enantioselectivity of lipase. *Organic Letters*, 3: 1507-1509) and (Lau, R. M. , et al. 2000 *Organic Letters*, 2: 4189) ].

$$(\quad 9 \quad 11 \quad ), (\pm) -1 - \quad -2 - \quad \text{(PMA)}$$

가 . , ,  
PMA PGAEA P  
MA

가 1, S- ( ), ( ), ( ), 1- 가 ) .  
2.2.2- 2.2.2-

, 1 -

가

가

가

가

n -

가

0.5%

85%

가

가 , 가

，  
PGA

2가

2가

PGAF

$$\left( \quad , \quad \right) ,$$





, 15

PMA 가

32  
(antipodal)

PEA 가

(Hoff et al. (1996) Tetrahedron: Asymmetry 7: 3181-3186)

가  
)

가

(

가 ,

(CIDR)

( )  
(Sharpless)

, TiC14

가

가

mmol ( ); μmol ( ); nmol ( ); pmol ( ); g ( ); mg ( ); μg ( ); ng ( ); L ( ); Mℓ ( ); μℓ ( ); cm ( ); mm ( ); μm ( ); nm ( ); % C (% ); ee ( ); E ( ).

1

P-

( 1 - - 2 - , PM).

( 1 - - 2 - , PMA).

( 1 - - 2 - , PE).

( 1 - - 2 - , PEA).

n- ( 1 - n - - 2 - , PnP).

n- ( 1 - n - - 2 - , PnPA).

( 1 - - 2 - , PiP).

( 1 - - 2 - , PiPA).

n- ( 1 - n - - 2 - , PnB).

n- (1-n- -2- , PnBA).  
t- (1-tert- -2- , PtB).  
t- (1-tert- -2- , PtBA).  
(1- -2- , PPh).  
(1- -2- , PPhA).

, (ChiroS  
creen) TM EH (Altus Biologics Inc. (Cambridge, MA) ), (Chirazyme)( ) amp  
; 2, G (Roche Molecular Biochemicals (Mann  
heim, Germany; US distribution via BioCatalytics Inc., Pasadena, CA) ), TM TM (Therm  
oCat TM QuickScreen TM ) (Thermogen Inc. (Lemont, IL) ),  
B (Fluka BioChemika AG (Buchs, Switzerland) )  
(Amano Pharmaceutical Co. (Nagoya, Japan) ), (Novo Nordisk),  
(Genencor International (Rochester, NY) ) . 4 -20

, (HPLC- ), , (KH<sub>2</sub>PO<sub>4</sub>, 99.0% min.)  
(Na<sub>2</sub>HPO<sub>4</sub>, 99.0%) (Fisher Scientific) . (S)-  
( T67893, 607). 29.  
6 mol% KH<sub>2</sub>PO<sub>4</sub> 70.4 mol% Na<sub>2</sub>HPO<sub>4</sub> × H<sub>2</sub>O , pH 7.2  
/ - (Sigma-Aldrich)  
: PM (99.5%), PMA (99.5%), PEA (95%), PnP (99%), PnB (99%), PtB PPh (93%, 7% ( )  
) ; DPPh ). PE, PiP, PiPA, PnPA, PnBA, PPhA (The Dow Chemical Company) . PtBA  
( ) - PtB (1:2 ) 5 mg/Ml L-10 (Roche Molecul  
ar Biochemicals)

가 가 가 GC  
가 . , P- .  
, (S)-PM (S)-PMA ( 2 ), GC , (S)-PM (S)-PMA  
. , (S)-PMA 가 (R)-PMA ( 4.1 4.24 ),  
가 - (S)-PM (R)-PM  
P- , P-  
(S)-PE (S)-PEA, (S)-PnP (S)-PnPA, (S)-PnB (S)-PnBA, (S)-PPh (S)-PPhA 가 ( )  
A, PPh PPhA (S)- 1- -2- 1 -2- ( )  
1- -2- ) 1

6890 , (FID) LEAP-CTC (100 )가  
GC P- 5가 GC  
, -DEX 325 (30 m x 0.25 mm ID 0.25 μm  
) (Supelco ) PM PMA 70 120 10 /  
, 150 200 250 . 18.0 psi ( )  
1 (1.0 μl). 200:1 25:  
0.5% r <sup>2</sup> >0.99 0.005

. PE, PnP, PiP, PnB, PPh  
(S)-  
(S)- (R)- . (±)-PM : (±)  
-PM (2.811 ), (S)-PMA (4.104 ), (R)-PMA (4.246 ), (S)-PE (3.203 ), (R)-PE (3.248 ), (S)-PEA (4.774 ), (R)-PEA (4.936 ), (S)-PnP (4.157 ), (R)-PnP (4.224 ), (S)-PnPA (6.0 ), (R)-PnPA (6.145 ),  
, (S)-PiP (3.629 ), (R)-PiP (3.718 ), (S)-PiPA (5.316 ), (R)-PiPA (5.448 ), (S)-PnB (5.394 ), (R)-PnB (5.484 ), (S)-PnBA (7.42 ), (R)-PnBA (7.545 ), (S)-PtB (5.559 ), (R)-PtB (5.908 ), (S)-PtBA (7.529 ) (R)-PtBA (7.679 ).

(±)-PM 20.0 psi ( ) -Dex 120 50 150 10 /  
elco ) 200:1 25:1 (30 m x 0.25 mm ID 0.25 μm ) (Sup  
, 200 250  
(R)-PM 3.136 3.192 (1.0 μl). (S)-PM

---

4 LC , (DAD), 200 200 가 - (Pe  
rkin-Elmer) 200 DOWANOL ( ) PPh (1- -2- ; PPh)  
0.65 Mℓ/ 35 10/40/50 / /  
al Technologies, Inc., Exton, PA 6.0 , 7.3 , 12.6 13.1 가 OD-RH (4.6 x 150 mm; Chir  
PhA PPh (DPPh; PPh) PPh ee 7% ) , PPh PPhA ( , DPPhA  
, )

2

(S)-PM (S)-PMA

(S)-1- -2- [(S)-PM]

3 100 Mℓ , , 가 / ,  
가 (22.99 g) , (0.0322 g) [  
(S)-PO; 45 T67893, Chirex 607] 5 Mℓ (S)-  
가 12.19 g PO (PM ) GC ( ) 가  
0.0294 g KOH 가 50 15 150 GC 0.007%  
(S)-PO . PM 91 118 (PM-2) 3.2% 2- 15 Mℓ  
가 GC 95.4% 1- -2- 2- -1-  
(PM-1)

(S) - 1 - - 2 - [(S)-PMA]

25 Mℓ	4.0 g (0.044 mole)	(S)-PM-2/(R)-PM-1	0.02 g	가
가	118	2	4.7 g (0.046 mole)	가
PMA-2	1 PMA-2	가 (S)-	1%	GC-
			PMA-2	PMA-1
			PMA-1	1
		가 (R)-2-	-1-	(R) (S) PMA-1
가	PMA-2			
2.44 g (0.024 mol)		가	CO <sub>2</sub>	1
5.0 g	가	GC	가	95% 95-137
1: 2.7%).				(S-PMA-2: 92.6% R-PMA-

3

## PMA 가 :

110 가 PMA

[ 1 ]

	( )	(S) - PMA (% v/v)	(R) - PMA (% v/v)	PMA (% ee)	
1	L-2, lyo	B	0.0642	0.0001	99.7% S

		(Roche Molecular Biochem.)				
33	SP-435	(Novo Nordisk)	B	0.0593	0.0001	99.7% S
49	13	(Altus Biologics, Inc.)	B	0.0775	0.0001	99.7% S
106	B,	(Fluka Biochemika)	B	0.0732	0.0001	99.7% S
91	LP 'S'	(Amano)		0.0666	0.0001	99.7% S
115		(Fluka Biochemika)		0.0567	0.0001	99.6% S
5	L-6	(Roche Molecular Biochem.)		0.0594	0.0050	84.5% S
95	PS-C I	(Amano)		0.0894	0.0157	70.1% S
38	2	(Altus Biologics, Inc.)		0.0707	0.0186	58.3% S
66	E001	(Thermogen, Inc.)		0.0043	0.0431	81.9% R
67	E002	(Thermogen, Inc.)		0.0001	0.0208	99.0% R
68	E003	(Thermogen, Inc.)		0.0082	0.0476	70.6% R
1	GC/FID		20		0.5%	
PMA (% v/v)	1.0 mg/Mℓ		1:5	%	/	

## 4

가 :

), (% ee 가 ), 가 , ( 가 ), (가 가 ,

가 1.8 Mℓ  
0.5 Mℓ  
L-2, lyo., B, 120 U/mg lyo  
(300 rpm) 10% (v/v) CAL-B (30  
1:100 P-  
CAL-B 가

2 ( 0.5)

2 가

가

2 가

가

2

2

CAL-B (L-2) (PMA) 가 2  
10% (v/v) PMA 0.5 (50% v/v)  
C  
AL-B (L-2) . 30 16 , GC

% (v/v) , (S)-PMA 50% (v/v) PMA (50% (v/v) (S)-PMA (S)-PMA 가  
). 50% (v/v) 99% ee (S)-PMA 99% ee  
10% (v/v) PMA 가  
(S)-PMA

2

가 PMA

2

PMA 가 10% 25% (v/v) 가 50% (v/v) (S)-PMA  
 가 99% ee 87% ee . 50% PMA 25%  
 40% 83% ee 66% ee (S)-PMA

10% (v/v) PMA가 (S)-PMA 99% ee  
 ) PMA . (S)-PMA 93% ee 20% (v/v

10% amp; 25% PMA

가 PM

CAL-B (L-2)가 PM . PM . PM . PM .

• (v/v) 가 PM 10% (v/v) PMA 가

99,5% ee (S)-PMA 2 , 20

가 (S)-PMA 가 ~96% ee

가 (0 50%) 2

가 25% (v/v)

pH 3.5 4.5  
pH 가 ( ).

(Indlekofer, M. et al. (1996) Biotechnology and Bioengineering, 52:459-471; and Indlekofer, M. et al. (1995) Biotechnology Progress 11:436-442).

가

50% (v/v) PMA 1 mg/Mℓ CAL-B (L-2 lyo.) 2 (25% (v/v))  
 0, 66 200 mM (pH 7.2) 44 PMA 가 9  
 3% ee 84% ee (S)-PMA 가 pH 3.0-3.  
 5, 4.0-4.5 4.5 , 66 mM 200 mM

2	가	가	PMA
2 (0.2 CAL-B ( L-2 lyo.) .	가 % ee	가	PMA 1 mg/Ml
99.5% ee MA e	(S)-PMA . 30% (v/v) 40% (v/v) PMA . 20% (v/v) : 20% (v/v), 25% (v/v) 40% (v/v) 가 e (S)-PMA	25% (v/v) PMA 64 97.5% ee 98.5% ee 97% ee	64 95.5% ee 92% e 가
PMA가 가 가	, 25% (v/v) PMA ( 2 ).		

50%	2	PMA 가					
50% (v/v)	가 2	10% (v/v) PMA 1.0, 0.5, 0.1, 0.05, 0.01, 0.001 mg/Mℓ		가	CAL-B (	L-2 lyo., 120 U/	
mg )		.	.				
2 , 1.0 0.5 mg/Mℓ	가 .72	PMA (S)-	가				9
8% ee	,	0.01 mg/Mℓ	0.5	1.0 mg/Mℓ	(S)-PMA	(S)	9
9.5% ee	.	,	0.5	1.0 mg/Mℓ	(50%)	(S)	.
-PMA	25%	10%	가	가			
, 가	25% (v/v) PMA 2.0, 1.0 0.5 mg/Mℓ	CAL-B (	L-2 lyo.) 가	4, 6	24	,	
3 99% ee	.	(S)-PMA	( 3).	(<60% ee	0.		
1 mg/Mℓ CAL-B (	L-2 lyo.)	30	(S)-PMA				
)							

PMA							
2.0	5.0 mg/Mℓ	CAL-B (L-2 lyo.) 가	25% (v/v) .	50% (v/v)		PMA	
2.0	5.0 mg/Mℓ 가	95% ee 가	(S)-PMA CAL-B 가	6 . 30	40% (v/v) (R)-PMA 가	PMA (S)-PMA % ee	

PMA 가  
 30 50 (5 ) PMA 25% (v/v) 1.0 0.5 mg/Mℓ CAL-B ( L-  
 2 lyo.) . , PMA 가 40 가 35 ,

(S)-PMA

50	5	40	
가	가	가	
가	40	, 35	
5			
가 P-		가	
가 :		가	
PMA P-	가	110 가	가
2		,	
4	24	가	0.5% (v/v)
PEA, PnPA, PiPA	PnBA	, PMA	2가
(S)-		(	GC
(S)-	85% ee	1	, 가
		)	
			(his)'
			가
			E001, E002
n, Inc.)			E003 (Thermoge

가 ~2 mg/Mℓ 0.5%, 10%, 25% (v/v)  
 0.5 Mℓ  
 2-5 PEA, PnPA, PiPA PnBA 가  
 ), 13 (Altus Biologics, Inc.), SP-435 (Novo Nordisk) CAL-B  
 가 B (CAL-B)가  
 L-2, Iyo., (Roche  
 CAL-B (Fluka BioChemika),

[ 2 ]

	( )	R-PE % ee (% v/v)	S-PEA % ee (% v/v)	E (% C) <sup>2</sup>
B,	B (Fluka Biochemika)	91.50% (7.16)	98.74% (6.52)	113 (53)
L-2, Iyo	B (Roche Molecular Biochem.)	85.19% (8.94)	98.45% (7.99)	60 (54)
13	B (Altus Biologics, Inc.)	88.81% (6.66)	98.44% (6.01)	81 (54)
SP-435	B (Novo Nordisk)	95.93% (8.46)	97.11% (6.95)	205 (55)
	(Fluka Biochemika)	49.92% (6.60)	97.61% (4.20)	12 (67)
PS-C II				

	(Amano)	88.98% (8.01)	91.35% (7.49)	55 (52)
2	(Altus Biologics, Inc.)	90.09% (8.90)	88.52% (8.26)	57 (52)
PS	(Amano)	90.43% (6.84)	87.64% (6.64)	57 (50)
	B (Fluka Biochemika)	92.22% (5.31)	74.12% (5.68)	55 (46)
L-6	(Roche Molecular Biochem.)	93.40% (5.03)	57.12% (6.19)	52 (40)
<sup>1</sup> GC/FID		24	PEA	
10% (v/v)	2.0 mg/Ml	1:10	% (v/v)	
<sup>2</sup> E = $\ln((1 - ee\%) PEA)/(1 + ee\% PEA/ee\% PE)) / \ln((1 + ee\% PEA)/(1 + ee\% PEA/ee\% PE))$ %, %C: [(S)PE + (R)PE] / [(S)PEA + (R)PEA + (S)PE + (R)PE] x 100				

[ 3]

	( )	( )	R-PnP % ee (% v/v)	S-PnPA % ee (% v/v)	E <sup>2</sup> (% C)		
L-2, lyo	B (Roche Molecular Biochem.)	4	99.07% (12.86)	95.53% (6.13)	827 (67)		
, L-2, c.-f., C2, lyo	B	1	98.84% (6.88)	92.86% (3.24)	587 (67)		
		4	96.33% (6.96)	91.14% (2.59)	171 (72)		
L-6	(Roche Molecular Biochem.)	4	92.79% (7.22)	73.16% (4.58)	59 (59)		
LP S	(Amano)	1	80.46% (7.39)	94.45% (5.96)	33 (57)		
		4	50.12% (9.36)	90.42% (2.98)	9 (80)		
<sup>1</sup> GC/FID		(300 rpm) 30					
PnPA 10% (v/v)	2.0 mg/Ml	1:100					
% (v/v)	.1a	53.2 mg/Ml	.				
<sup>2</sup> E (%):							
E = $\ln((1 - ee\%) PnPA)/(1 + ee\% PnPA/ee\% PnP)) / \ln((1 + ee\% PnPA)/(1 + ee\% PnPA/ee\% PnP))$ %, %C : [(S)PnP + (R)PnP] / [(S)PnPA + (R)PnPA + (S)PnP + (R)PnP] x 100							

[ 4]

	( )	( )	R-PIP % ee (% v/v)	S-PIPA % ee (% v/v)	E <sup>2</sup> (% C)
L-2, lyo	B (Roche Molecular Biochem.)	24	94.4% (3.10)	94.14% (2.32)	149 (54)
, L-2, c.-f., C2, lyo	B (Roche Molecular Biochem.)	1	96.5% (3.39)	98.76% (1.16)	287 (60)
L-6	B (Roche Molecular Biochem.)	24	94.86% (3.03)	84.42% (2.25)	102 (56)
L-10	B (Roche Molecular Biochem.)	24	94.8% (2.99)	79.0% (2.3)	90 (54)
19	(Altus Biologics)	1	94.46% (3.16)	95.5% (3.06)	135 (51)
LPS	(Amano)	1	95.47% (3.02)	95.27% (2.89)	164 (51)
PS	(Amano)	24	95.64% (3.14)	94.12% (2.31)	160 (57)
<sup>1</sup>	GC/FID , PiPA 10% (v/v) 2.0 mg/Ml % (v/v) . 1a		(300 rpm) 30 1:100		
<sup>2</sup>	' (E):				
$E = \ln((1 - ee\% PIPA)/(1 + ee\% PIPA/ee\% PnP)) / \ln((1 + ee\% PIPA)/(1 + ee\% PIPA/ee\% PIP))$ %, %C: $[(S)PIP + (R)PIP] / [(S)PIP + (R)PIP + (S)PIP + (R)PIP] \times 100$					

[ 5]

	( )	( )	R-PnB % ee (% v/v)	S-PnBA % ee (% v/v)	E <sup>2</sup> (% C)
L-2, lyo	B (Roche Molecular Biochem.)	4	99.95% (3.10)	96.5% (2.81)	>500 (52)
, L-2, c.-f., C2, lyo	B (Roche Molecular Biochem.)	4	99.95% (2.24)	98.29% (1.16)	>500 (66)
L-6	B (Roche Molecular Biochem.)	4	87.01% (2.88)	81.19% (2.89)	36 (49)
L-8	B (Roche Molecular Biochem.)	24	99.95% (1.8)	75% (1.05)	>500 (60)
<sup>2</sup>		24			

	(Altus Biologics)		91.26% (1.97)	63.64% (1.17)	42.1 (59)
1	GC/FID	,	(300 rpm) 30		
PnBA 10% (v/v)	2.0 mg/Mℓ		1:100		
% (v/v)	. 1a	53.2 mg/Mℓ	.		
2	' (E):				
E = $\ln((1 - ee\% \text{ PnBA})/(1 + ee\% \text{ PnBA}/ee\% \text{ PnP})) / \ln((1 + ee\% \text{ PnBA})/(1 + ee\% \text{ PnBA}/ee\% \text{ PnB}))$					
%	, %C:				
[ (S)PnB + (R)PnB ] / [ (S)PnBA + (R)PnBA + (S)PnB + (R)PnB ] x 100					
500	E	>500	.	.	.

CAL-B      PEA, PnPA, PiPA      PnBA      (      2-5      ),  
 L-2, lyo      L-2, c.-f., C2, lyo      PPhA  
 가      . 1.0 mg/Mℓ      L-2, lyo.      26.6 mg/Mℓ      L-2, c.-f., C2, lyo      PPhA  
 10, 15, 25, 35      50% (v/v)      0.2 Mℓ      PPhA      가  
 .      L-2, c.-f., C2, lyo.      (S)-PPhA      (R)-PPh      가 25%  
 가      99% ee (50%      )      . (S)-PPhA      35% (81% ee)      50%  
 (74% ee)      가      L-2, lyo      10%      가 (99% ee      )  
 (S)-PPhA      , 15%, 25%, 35%      50% (v/v)      가      PPhA가      95  
 % ee, 86% ee, 79% ee      69% ee      .

CAL-B

P-      CAL-B (      L-2 lyo.)  
 .      가      6

[ 6 ]

	(v/v%)	( )	(mg/Mℓ)	1	( )	(%)	(R)-% ee	(S)-% ee
PMA	20	40	26.6	4		37.6	n.d.	>99
	20	40	26.6	20		48.9	n.d.	>99
	25	40	26.6	2		35.6	n.d.	>99
	25	40	26.6	30		54.9	n.d.	97.0
	35	40	26.6	22		38.7	n.d.	95.1
	45	40	26.6	22		34.2	n.d.	94.0
	50	40	26.6	30		33.4	n.d.	92.2
	75	40	26.6	6.5		29.3	n.d.	79.1
PEA	10	40	26.6	1.5		53.2	97.3	98.7
	20	40	26.6	3		55.2	96.4	97.1
	25	40	26.6	1.5		56.2	97.3	95.3
	30	40	26.6	3		51.7	96.8	94.6
	35	40	26.6	5		54.4	96.9	93.3
	40	40	26.6	5		51.1	97.3	91.7
	50	40	26.6	20		43.2	97.1	88.2
PnPA	15	30	26.6	4		73.2	>99	91.4

	25	30	26.6	4	59.6	>99	89.7
	35	30	26.6	4	63.2	>99	86.0
	50	30	26.6	24	55.6	>99	80.3
PiPA	15	30	26.6	24	66.2	95.4	90.2
	25	30	26.6	24	68.1	96.4	89.2
	35	30	26.6	24	55.6	97.3	85.6
	50	30	26.6	24	42.1	97.4	79.7
PnBA	15	30	26.6	4	81.7	97.9	93.6
	25	30	26.6	4	50.4	98.9	87.5
	35	30	26.6	4	48.5	>99	83.5
	50	30	26.6	4	47.8	>99	76.9
PPhA	10	30	26.6	4	50.0	>99	>99
	15	30	26.6	4	68.6	>99	>99
	25	30	26.6	4	50.6	>99	>99
	35	30	26.6	24	44.8	>99	81.5
	50	30	26.6	24	41.3	>99	73.7

CAL-B가 PEA, PnPA, PiPA, PnBA PPhA 가 (S)-  
(R)- 가 . CAL-B가

CAL-B (50% 70% v/v) 7 . ,  
가 7

[ 7 ]

6

가

CAL-B PM

(  
0.5 Mℓ)  
CAL-B  
5.0 mg/Mℓ CAL-B (L-2 lyo.)  
10% (v/v) PM  
8

[ 8 ]

/	PM (% v/v)	PM (% v/v)	(S)-PMA (% v/v)	(R)-PMA (% v/v)	(R)-PMA (% ee)
	10%	1.15	9.40	12.48	14%
/ (8:1)	10%	0.08	11.06	12.20	5%
/ (8:1)	10%	0.09	8.92	9.98	6%
/ (8:1)	10%	6.85	0.62	3.70	71%
	10%	5.80	0.86	9.19	83%
1	16	GC/FID			

16

CAL-B 가

( 8 )

PM

가

90% (v/v)

A 1

98% ee

가  
가  
가  
5.0 mg/Mℓ CAL-B (L-2 lyo.)  
50% (v/v) PM  
50% (v/v) PM  
(R)-PM

CAL-B

가 P-

P-

PM, PE, PnP, PiP, PnB PPh

(R)-

CAL-B

가

7

), (% ee ( ), ) 가 , ( ), ( 가 , ,  
가

가 가 . .

75/25% (v/v) PM/VA 80/20% (v/v) PPh/VA / 1.0 Mℓ , PM PPh  
 26.6, 13.3 6.7 mg/Mℓ  
 B ( L-2, c.-f., C2, Iyo.) PMA PPhA (R)- 가  
 가 % ee 가 , , ,  
 PM 3가 가 , ,  
 ) ~10% PPh 4  
 (R)-PMA (R)-PPhA % ee % 가  
 (R)-PPhA % ee % 가  
 (6.6 mg/Mℓ)  
 가  
 PM 가  
 가  
 9

PM CAL-B 가  
 ,  
 -20 30  
 75/25% 70/30% (v/v) PM/ 1.0 Mℓ , PM  
 30, 20, 4 -20 (±2 ) 26.6, 13.3, 6.7, 3.3 1.7 mg/Mℓ  
 B ( L-2, c.-f., C2, Iyo.) 가  
 (-20 ) % ee (R)-PMA 가  
 가  
 9

## [ 9 ]

		/	( )	가 1 <sup>1</sup> (mg/Mℓ)	( )	(%)	(S)- % ee	(R)- % ee
PM	VA	75/25	30	26.8	2	44.6	n.d.	90.34
				26.8	8	44.8		82.32
PM	VA	70/30	4	26.8	4	20.7		95.3
				26.8	24	53.6		87.6
PM	VA	70/30	-20	26.8	4	8.3		97.6
				26.8	52	45.5		96.3
PM	VA	75/25	30	13.4	2	37.3		93.2
				13.4	8	45.9		88.7
PM	VA	70/30	4	13.4	4	15.3		96.5
				13.4	26	51.9		91.7
PM	VA	70/30	-20	13.4	4	5.7		98.0
				13.4	52	35.5		97.7
PM	VA	75/25	30	6.8	2	24.3		94.7
				6.8	8	46.9		91.7
PM	VA		20	6.8	6	24.5		92.1
				6.8	22	42.4		87.7
PM	VA		4	6.8	6	20.0		96.6
				6.8	48	46.0		93.0

PM	VA		-20	6.8	6	5.5		98.4
				6.8	48	26.3		97.9
PM	VA	75/25	30	3.4	2	12.1		94.4
				3.4	6	25.5		92.5
PM	VA		20	3.4	6	17.8		93.5
				3.4	22	32.9		91.3
PM	VA		4	3.4	6	11.4		97.0
				3.4	48	40.4		94.6
PM	VA		-20	3.4	6	2.6		98.5
				3.4	48	14.6		98.3
PM	VA	75/25	30	1.7	2	6.7		94.8
				1.7	6	23.1		92.6
PM	VA		20	1.7	6	11.0		94.6
				1.7	22	30.2		92.8
PM	VA		4	1.7	6	6.3		97.3
				1.7	48	30.1		96.3
PM	VA		-20	1.7	6	1.6		98.3
				1.7	48	9.8		98.4
<sup>1</sup> B, ( L - 2, c.f., C2, lyo (~10 U/mg, Roche Molecular Biochemicals) )								

.	( )	,	(<3%)	PM	PPh
CAL-B	10	50	150	(E)	, 70 % (v/v)
		PM, PE, PnP, PiP, PnB	PPh		

[ 10 ]

	( )	(S)-OH % ee	(R)-OAc % ee	E
PE	6	37%	96%	71
PnP	5	95%	89%	65
PiP	6	92%	87%	49
PnB	4	>99%	82%	59
PPh	4	>99%	94%	160
<sup>1</sup> 0.5 M $\ell$ , 1.0 mg/M $\ell$ , 70% (v/v) ,				

(R)-  
5 ) . , (CAL-B  
50% , PEA 96% ee  
80% ee ( , PPhA 95% ee  
( , 87%, 89% 82% ee , P-  
)- PnBA , (R)- (R)-  
). (R)

가 6.6 mg/Mℓ L-2, c.-f., C2, Iyo., PE 1.0  
5% 55% (v/v) , 1.0 Mℓ . PE 1:1 1:2  
59% (v/v) ,  
PnP 가 (BA), 31% (EPA),  
(EtCA), (EtFA),  
(VA), (EMA), 2,2,2-  
(VP) 30 24  
(R)- % ee % 11  
. (TfEB), (IPA),  
. (DK) (S)-

## [ 11 ]

	1 / (v/v)	( )	2 (mg/Mℓ)	( )	(%)	(S)- ee (%)	(R)- ee (%)
PE	BA	47/53	30	6.7	20	16.9	11.7
	BA	47/53	30	6.7	24	17.8	9.5
	EPA	39/61	30	6.7	20	2.1	-1.5
	EtA	54/46	30	6.7	20	17.5	9.8
	EtA	54/46	30	6.7	24	18.4	3.1
	ETFA	42/58	30	6.7	20	1.0	-9.4
	IPA	51/49	30	6.7	20	51.6	72.4
	IPA	51/49	30	6.7	24	54.5	77.5
	VA	55/45	30	6.7	20	44.7	51.8
	VA	55/45	30	6.7	24	47.4	54.9
	EMA	47/53	30	6.7	24	1.0	10.7
	TFEB	38/62	30	6.7	20	60.6	54.5
	TFEB	38/62	30	6.7	24	63.9	58.7
	VP	51/49	30	6.7	20	62.5	73.2
	VP	51/49	30	6.7	24	65.3	77.9
PnP	BA	50.5/49.5	30	6.7	2	7.4	5.2
	BA	50.5/49.5	30	6.7	20	17.2	17.4
	BA	34/66	30	6.7	6	17.1	16.4
	BA	34/66	30	6.7	24	24.1	23.9
	EtA	58/42	30	6.7	4	11.4	9.5
	EtA	58/42	30	6.7	24	18.7	17.2
	EtA	41/59	30	6.7	4	16.0	15.3
	EtA	41/59	30	6.7	24	25.7	25.1
	IPA	55/45	30	6.7	4	33.5	38.6
	IPA	55/45	30	6.7	20	54.9	98.7

	IPA	38/62	30	6.7	6	45.1	62.5	96.9
	IPA	38/62	30	6.7	20	58.7	98.0	88.1
	VA	59/41	30	6.7	1	32.0	35.1	97.4
	VA	59/41	30	6.7	6	52.6	85.2	93.6
	VA	59/41	30	6.7	20	60.7	98.3	74.3
	VA	42/58	30	6.7	1	39.3	47.2	96.7
	VA	42/58	30	6.7	6	56.5	95.5	90.1
	VA	42/58	30	6.7	20	66.1	97.7	66.8
	TFEB	47/53	30	6.7	20	61.9	77.2	81.0
	TFEB	47/53	30	6.7	24	61.6	76.1	81.0
	TFEB	31/69	30	6.7	20	59.5	71.3	80.4
	TFEB	31/69	30	6.7	24	62.9	80.5	81.4
	VP	55/45	30	6.7	6	62.7	86.7	81.8
	VP	55/45	30	6.7	24	66.8	99.2	82.6
	VP	38/62	30	6.7	6	61.6	93.8	82.4
	VP	38/62	30	6.7	24	68.2	99.0	82.7

가

[ 12 ]

		/ <sup>1</sup> (v/v)	/	<sub>2</sub> (mg/Mℓ)	( )	(%)	(S) - ee (%)	(R) - ee (%)
PE	IPA	51/49	1/1	6.7	20	51.6	72.4	95.6
	IPA	51/49	1/1	6.7	24	54.5	77.5	95.3

	VA	55/45	1/1	6.7	20	44.7	51.8	95.2
	VA	55/45	1/1	6.7	24	47.4	54.9	95.0
PnP	IPA	55/45	1/1	6.7	4	33.5	38.6	97.8
	IPA	55/45	1/1	6.7	20	54.9	98.7	91.8
	IPA	38/62	1/2	6.7	6	45.1	62.5	96.9
	IPA	38/62	1/2	6.7	20	58.7	98.0	88.1
	VA	59/41	1/1	6.7	1	32.0	35.1	97.4
	VA	59/41	1/1	6.7	6	52.6	85.2	93.6
	VA	59/41	1/1	6.7	20	60.7	98.3	74.3
	VA	42/58	1/2	6.7	1	39.3	47.2	96.7
	VA	42/58	1/2	6.7	6	56.5	95.5	90.1
	VA	42/58	1/2	6.7	20	66.1	97.7	66.8
PnB	IPA	57/43	1/1	6.7	4	40.1	53.3	96.7
	IPA	57/43	1/1	6.7	6	44.8	61.2	95.9
	IPA	57/43	1/1	6.7	20	58.0	99.5	81.7
	IPA	40/60	1/2	6.7	6	47.6	67.4	95.4
	IPA	40/60	1/2	6.7	20	58.7	>99	79.2
	IPA	40/60	1/2	6.7	24	60.3	>99	74.4
	VA	61/39	1/1	6.7	4	52.1	82.7	92.6
	VA	61/39	1/1	6.7	6	54.3	86.4	89.3
	VA	61/39	1/1	6.7	20	66.5	>99	56.7
	VA	44/56	1/2	6.7	2	38.5	51.5	95.2
	VA	44/56	1/2	6.7	6	55.9	>99	87.0
	VA	44/56	1/2	6.7	20	68.1	>99	53.5
PPh	IPA	57/43	1/1	6.7	6	29.8	51.3	96.4
	IPA	57/43	1/1	6.7	20	43.5	97.9	93.1
	IPA	57/43	1/1	6.7	24	44.1	98.2	92.0
	IPA	40/60	1/2	6.7	6	35.8	62.4	95.0
	IPA	40/60	1/2	6.7	20	44.5	96.1	90.5
	IPA	40/60	1/2	6.7	24	45.0	98.1	89.5
	VA	61/39	1/1	6.7	6	38.4	73.3	95.3
	VA	61/39	1/1	6.7	20	45.8	97.6	87.5
	VA	61/39	1/1	6.7	24	46.2	98.1	86.2
	VA	44/56	1/2	6.7	4	39.9	73.6	93.7
	VA	44/56	1/2	6.7	6	43.1	>99	92.8
	VA	44/56	1/2	6.7	20	47.6	98.1	81.7
1	:			(IPA)			(VA)	
2		B,		(			L-2, c.f., C2, lyo	
		(~10 U/mg, Roche Molecular Biochemicals)		)				

PM PPh CAL-B ( ) . 80% 84% 가  
 , 50% . 가  
 .

가

13

[ 13 ]

		/	( )	<sup>1</sup> (mg/Mℓ)	( )	(%)	(S)- ee (%)	(R)- ee (%)
PM	VA	50/50	30	1.0	2	59.9	n.d. <sup>2</sup>	94.8
					22	84.3	n.d.	56.2
PM	VA	70/30	30	1.0	2	59.6	n.d.	94.3
					22	68.7	n.d.	81.6
PnB	VA	50/50	30	1.0	2	51.9	75.3	86.2
					22	70.5	99.0	47.6
PnB	VA	70/30	30	1.0	2	52.4	79.0	88.1
					6	59.9	99.0	76.3
PE	VA	50/50	30	1.0	4	39.6	95.7	95.7
					22	52.3	77.2	94.3
PE	VA	70/30	30	1.0	4	33.8	32.9	95.9
					22	39.6	45.4	95.7
PiP	VA	50/50	30	1.0	2	53.8	73.2	87.7
					22	65.4	95.1	73.2
PiP	VA	70/30	30	1.0	2	43.9	50.4	91.1
					22	63.6	96.9	79.4
PnP	VA	50/50	30	1.0	2	48.7	70.3	94.4
					22	67.6	99.0	59.7
PnP	VA	70/30	30	1.0	2	47.5	67.6	94.6
					5	58.4	95.4	89.0
PPh	VA	50/50	30	1.0	2	38.9	74.7	94.9
					22	52.5	99.0	68.0
PPh	VA	70/30	30	1.0	2	33.3	62.1	95.9
					6	46.0	99.0	92.2
PtB	VA	73/27	30	6.7	6	41.6	54.4	>99
					20	55.6	96.5	>99
PtB	VA	76/24	30	6.7	6	41.8	54.9	>99
					20	54.5	91.6	>99

<sup>1</sup> B ( L-2, Iyo (~120 U/mg, Roche Molecular

Biochemicals) ). L-2, c.f., C2, Iyo (~10 U/mg, Roche Molecular

Biochemicals) PtB

<sup>2</sup> n.d.

가

가 CAL - B

가 가

25, 35    45% (v/v)              PMA    13 mg/Ml              L-2, c.-f., C2 ( 10 U/mg)    0  
 .5 Ml                                 .              300 rpm                      40                      .              24

(S)-PMA 92% ee . 35% 45% , 25% PMA 3  
 (S)-PMA >96-98% ee . 가 20% 25% 가  
 L-2, c.-f., C2 , (S)-PMA 20% 25%  
 30 97% ee .

PMA 25% (v/v) PMA 3500 (New Brunswick Scientific  
 ) 1.5 . 26.6 mg/Mℓ L-2, c.-f., C2 ( 280 U/Mℓ) 가  
 , 25% PEA 2 5 15 . ,

PMA 가 .15 (S)-PMA .15 (R)-PM  
가 .15  
>99.5% ee >85% ee .

L-B (20%) 가 ) pH 7.2 37 가 .  
 가 . PEA 32 가 , 8 ( 가 18 10%) 8, 10, 16 25 (S)-PEA (R)-PEA (% ee) , (S)-PEA (% R)-PEA ,

| -2 C -f C2 | : 가

		PPh	L-2, c.-f., C2 (6.6 mg/Ml)	1.0-L	<50%
70/30	76/30	PPh/VA	% ee	(R)-PPhA	
		, 70/30 PPh/VA	4		
(S)-PPh	(R)-PPhA			>90% ee	95% ee

5-8

PGEA 1.0- 가 (S)-PGA  
E (R)-PGAEA

[ 14]

			/ (v/v)	( )	% (%)	CAL-B, L-2, C2 (mg/Mℓ)		(S)- ee (%)	(R)- ee (%)
1	PM	VA	62/38	4	65 (68)	10.00	10	95.47	80.02
2	PM	IPA	69/31	4	40 (~43)	13.4	3	27.56	95.44
3	PnP	VA	69/31	4	65 (~63)	10	21	98.6	88.2
4	PnP	VA	78.5/21.5	4	40 (~44)	3.3 - 6.6	8	47.55	97.1
5	PnB	IPA	69/31	4	61 (~59)	6.7 - 18.6	7	99.9	92.1
6	PnB	IPA	73/27	4	50 (~45)	6.7	8	55.7	97.7
7	PtB	VA	73/27	24	60 (~56)	6.7	12	95.5	99.6
8	PPh	VA	76/24	20	56 (~45)	6.7	5	62.64	96.06
9	PPh	VA	70/30	4	66 (~51)	6.7	2	78.9	97.08

9

## PMA

\_\_\_\_\_ :

1.8 Mℓ L-2 C2 가 . 1 - tert - PtB - 2 - (PtB), ( ) . 1  
00%

	( %)	(mg/Mℓ)		PtB ( μ L)	( μ L)	%
1	PMA 50%	13.4	PtB	500	500	104
2	PMA 70%	13.4	PtB	700	300	45
3	70%	13.4	PtB	700	300	70
4	70%	13.4	PtB	700	300	66

1.0 Mℓ PtB 4 , 1 - tert - - 2 - 65 (PtBA), GC  
PM PMA

\_\_\_\_\_ :

15 DOWANOL PMA가 PtB (>99% ee) (R)-PtBA  
PMA (R)-PM ( ) , PtB 1 2 CAL-B가 (R)-PMA  
(S)-PMA (R)-PM

31%    20%    PtB                  , 50:50 (      1)    70:30 (      2)                  PtB/PMA

15

[ 15 ]


	( )	(S) - PtB (% ee)	(R) - PtBA (% ee)	PtB (%) <sup>1</sup>	(R) - PM (% ee)	(S) - PMA (% ee)	PMA (%)
1	0	0	0	0	0	0	0
	18	22	>99	23	93	22	12
	24	25	>99	25	96	24	13
	47	32	>99	30	86	28	16
	65	34	>99	31	84	28	17
2	0	0	0	0	0	0	0
	18	13	>99	15	94	39	19
	24	15	>99	17	92	43	21
	47	17	>99	19	87	49	24
	65	18	>99	20	84	48	26
3	0	0	0	0	- <sup>2</sup>	-	-
	18	73	>99	49	-	-	-
	24	84	>99	53	-	-	-
	47	95	>99	56	-	-	-
	65	94	>99	56	-	-	-
4	0	0	0	0	-	-	-
	18	11	>99	13	-	-	-
	24	12	>99	15	-	-	-
	47	15	>99	17	-	-	-
	65	15	>99	17	-	-	-

10

PMA

PtB/PMA . . . . . 30:70, 40:60, 50:50, 60:40 70:30  
 R-PtBA, S-PtB, R-PM S-PMA  
 PtB, PMA ( )  
 L-2 C2 . .

	/ ( )	(mg/Mℓ)	PtB (μL)	PMA (μL)	(%)
1	PtB/PMA (30:70)	13.4	300	700	244.09
2	PtB/PMA (40:60)	13.4	400	600	156.91
3	PtB/PMA (50:50)	13.4	500	500	104.61
4	PtB/PMA (60:40)	13.4	600	400	69.74
5	PtB/PMA (70:30)	13.4	700	300	44.83



[ 16 ]

	( )	(S)-PtB (% ee)	(R)-PtBA (% ee)	PtB (%) 1	(R)-PM (% ee)	(S)-PMA (% ee)	PMA (%) 2
1	0	1	71	1	91	1	0
	2	18	98	19	93	8	5
	5	36	>99	32	87	12	7
	20.5	57	>99	42	68	12	10
	51	52	>99	40	50	7	11
2	0	0	34	0	0	0	0
	2	16	>99	17	93	10	6
	5	30	>99	29	88	16	10
	20.5	45	>99	38	67	17	14
	51	50	>99	39	39	12	15
3	0	0	18	0	0	0	0
	2	12	>99	14	94	12	7
	5	23	98	24	90	21	12
	20.5	36	>99	33	72	25	17
	51	40	>99	34	49	19	19
4	0	0	8	0	0	0	0
	2	7	>99	8	93	10	6
	5	17	98	19	90	25	14
	20.5	28	>99	27	74	34	22

	51	31	>99	29	51	26	24
5	0	0	6	0	0	0	0
	2	4	98	6	93	10	6
	5	11	98	14	91	28	16
	20.5	20	>99	21	77	45	26
	51	22	>99	23	56	37	29

11

PMA

A

■ ■

PM . PM (PMA) 가 . PM #1 R-PM  
PMA 가 (#3) . PtB, (i) PMA PMA #2 (ii) ( )  
L-2 C2 .

		(mg/Mℓ)		(mL)	(mL)	
1		40.2	PtB	60	40 <sup>-1</sup>	1.5
2	#2	40.2	PtB	60	40 <sup>-2</sup>	-
3	#3	40.2	PtB	60	40 <sup>-3</sup>	-
<sup>1</sup>	1	40 Mℓ PMA		1.5, 3.0	4.5	PM -
<sup>2</sup>	2		40 Mℓ PMA			.
<sup>3</sup>	3		40 Mℓ PMA			.
1.75, 3.25	4.75					.

30 250 Mℓ 1 1.5  
PM PM , (30 ), 가 74 PMA .  
\_\_\_\_\_  
17 1 3 PtB (R)-PtBA 70% 46%  
3 (PM) 가  
(R)-PtBA >99% ee (R)-PM

1 (S)-PtB가 1 >84% ee  
 1 70% PtB  
 PtB  
 1.5, 3.0 4.5  
 (R)-PM

, (S)-PtB  
 (R)-PtBA  
 PMA  
 3 65.6% ee  
 1

가 (R)-PM  
 (R)-PMA

2

[ 17 ]

	( )	(S)-PtB (% ee)	(R)-PtBA (% ee)	PtB (%) <sup>1</sup>	(S)-PMA (% ee)	PMA (%) <sup>2</sup>	(R)- PM (% ee) <sup>3</sup>
1	0	0	0	0	0	0	
	0.5	10	>99%	12	16	9	
	1	16	>99%	18	24	14	
	1.5	21	>99%	22	29	16	70
	1.75	22	>99%	27	7	3	
	2	35	>99%	34	12	7	
	2.5	40	>99%	38	14	8	
	3	44	>99%	40	15	9	74
	3.25	46	>99%	53	6	-- <sup>4</sup>	
	3.5	60	>99%	56	8	--	
	4	65	>99%	58	8	--	
	4.5	71	>99%	59	8	--	66
	4.75	68	>99%	67	4	--	
	20.5	85	99	70	3	--	
2	0	0	0	0	0	0	
	0.5	10	99	13	16	9	
	1	17	>99%	19	24	13	
	1.5	21	>99%	22	29	16	
	1.75	22	>99%	23	29	17	
	2	25	>99%	25	31	18	
	2.5	26	>99%	26	32	19	
	3	27	>99%	27	32	20	
	3.25	28	>99%	27	32	20	
	3.5	28	>99%	27	32	21	
	4	29	>99%	28	32	21	
	4.5	29	>99%	28	31	21	
	4.75	29	>99%	28	31	21	
	20.5	36	99	32	15	26	
3	0	0	0	0	0	0	
	0.5	10	>99%	12	15	8	
	1	17	>99%	18	23	13	

	1.5	21	>99%	22	28	16	
	1.75	22	>99%	23	12	8	
	2	29	>99%	28	15	9	
	2.5	33	>99%	30	17	11	
	3	36	>99%	32	18	12	
	3.25	37	>99%	33	11	8	
	3.5	41	>99%	35	12	8	
	4	44	>99%	37	13	9	
	4.5	47	>99%	38	13	9	
	4.75	47	>99%	38	9	7	
	20.5	66	99	46	6	9	
<sup>1</sup>	PtB	PtBA		GC-FID ( )			
[	PtBA/	PtBA + PtB] x 100		.	.	.	
± 10%	1	>50% PtB	(>99% ee (R)-PtBA )	PtB			
<sup>2</sup>	PMA	GC-FID ( )		[ PM/	PM + PMA] x 100		
3				± 10%	.	.	
<sup>4</sup>	nd,	(R)-PM		PM		.	

B

:

50:50                    PtB/PMA                    100 Mℓ                    PM  
 .                        50 Mℓ      PMA                    .                    A  
 .

		(mg/Mℓ)		(mL)	(mL)	
1		40.2	PtB	50	50 1	1.5
2	#2	40.2	PtB	50	50 2	-
3	#3	40.2	PtB	50	50 3	-
<sup>1</sup>	1	50 Mℓ PMA	1.5, 3.0	4.5	PM-	.
<sup>2</sup>	2		50 Mℓ PMA		.	.
<sup>3</sup>	3		1		가 50 Mℓ PMA	.

:

B                    ( 18)                    A                    .                    1                    3                    PtB                    (R)-PtBA  
 .                    77%                    43%                    . 50%                    .                    ,                    ,                    3                    (PM)  
 A                    .                    .                    .                    .                    .                    .                    .  
 1                    (R)-PM                    .                    .                    .                    .                    .  
 ,                    3                    (S)-PtB                    60% ee                    .                    .                    .  
 (S)-PtB                    5                    >99% ee  
 (R)-PtBA                    5                    >80% ee

(R)-PM  
3

69% ee      87% ee

B      1  
PtB

1

[ 18]

	( )	(S)-PtB (% ee)	(R)-PtBA (% ee)	PtB (%) <sup>1</sup>	(S)-PMA (% ee)	PMA (%) <sup>2</sup>	(R)-PM (% ee) <sup>3</sup>
1	0	0	0	0	0	0	
	0.5	11	98	14	12	7	
	1	21	>99%	21	19	11	
	1.5	27	>99%	26	23	13	87
	2	45	>99%	46	10	4	
	2.5	55	>99%	50	11	5	
	3	59	>99%	51	11	5	70
	4	77	>99%	69	5	-- <sup>4</sup>	
	4.5	79	>99%	70	5	--	69
	5	80	>99%	76	3	--	
	5.5	80	>99%	76	3	--	
	6	83	>99%	77	3	--	
2	0	0	0	0	0	0	
	0.5	11	98	13	11	6	
	1	20	>99%	21	18	10	
	1.5	26	>99%	26	22	13	
	2	30	>99%	29	24	14	
	2.5	33	>99%	30	25	15	
	3	34	98	31	25	15	
	4	37	>99%	33	24	15	
	4.5	37	>99%	33	24	16	
	5	38	>99%	33	23	17	
	5.5	39	>99%	34	22	17	
	6	39	>99%	34	22	18	
3	0	0	0	0	0	0	
	0.5	10	98	13	11	6	
	1	19	99%	20	18	10	
	1.5	26	>99%	25	22	12	
	2	32	>99%	30	12	7	
	2.5	37	>99%	33	13	8	
	3	42	>99%	35	14	9	
	4	51	>99%	40	10	7	
	4.5	54	>99%	41	10	7	
	5	57	>99%	43	7	5	
	5.5	58	>99%	43	7	6	

	6	60	>99%	43	7	6	
<sup>1</sup>	PtB	PtBA		, GC-FID ( )			
[	PtBA/	PtBA + PtB] x 100	.				
± 10%	.	1 >50% PtB	(>99% ee (R)-PtBA)	.			
		PtB					
<sup>2</sup>	PMA	GC-FID ( )		[	PM/	PM + PMA] x 100	
		.		± 10%	.		
<sup>3</sup>		(R)-PM		PM	.		
<sup>4</sup>	nd,	.					

12

(a): (R,S)-1-tert-

(b): (S)-PtB/(R)-PtBA

(a)		2		1				
	, 3790 g	2		/S)-PtB/(R)-PtBA		5-L		
1/4'				(-15	)	SR-1		
			2/2	/		350 mmHg	47	가
		3.5		,		가	(S)-PtB/(R)-PtBA	
1/4'		6						
	, 4033 g		(S)-PtB/(R)-PtBA		5-L			2/1
/	6	36 mmHg	74	89	가	.24		
GC					b ( 7-16)		1265 g	98.4%
(S)-PtB	e (	20-24)		1990 g	99.5% (R)-PtBA			
	( , 200:1 )		(S)-PtB	(R)-PtBA	가 >99.5% ee			

(c - 1): (S) - PtB (S) - PG

10 Mℓ 2  
SA) . CaSO<sub>4</sub> (b) 5.0032 g (S)-PtB 0.1888 g p- (p-T  
100 가 13  
GC , (S)-PtB 98.6% 가 (S)-PG  
81.6% ( 18 ). (200:1 ) (S)-PG (S)-PG GC  
>99.5% ee

(c-2): (R)-PtBA (R)-PG 가

10 Mℓ 2  
p-TSA . . . . . (b) 5.0375 g (R)-PtBA, 15.0919 g 0.4671 g  
CaSO<sub>4</sub> 100 가 33  
GC ( 18 ). , (R)-PtBA 100%가 (200:1) (R)-PG (R)-PG  
86.5% GC  
>99.5% ee

(d): (S)-PG

5 Mℓ  
가 . . . . . (c-1)  
GC 89% PG 84-87 10 mmHg  
PG . . . . . GC-MS  
>99.5% ee . . . . . GC

(e): (S)-PtB 가

B . . . . . (b) (R)-PtBA (S)-PtB (S)-PtB (S)-Pt  
NaOH . . . . . (S)-PtB 19 10 N  
IR . . . . . >95% (99.5% ee) (S)-PtB (c-1)  
(b)

[ 19 ]

	%	(R)%	(S)PG	( )	( )		( )	( )
(S)-PtB	65.4	68.3		40-80	5.5	*	10.1	n.a. **
(S)-PtB	81	73.6		80	10.5	*	17	n.a. **
(S)-PtB	96.4	82.8		100	14.5	*	14	n.a. **
(S)-PtB	98.6	81.6		100	13	p-TSA	3.8	n.a. **
(S)-PtB (NaOH )	98.8	95.9		100	19	p-TSA	7.9	n.a. **
(R)-PtB	87.7	5.1		80	6.5	*	9.8	n.a. **
(R)-PtB	100	31.3		100	13.5	p-TSA	4.1	1
(R)-PtB	100	86.5		100	33	p-TSA	3.1	29

\* DOWEX DR-2030  
( >2M)  
\*\*

(57)


1.

|

가

가

&lt; |&gt;



, R

2.

1 , 가 10% v/v

3.

1 2 , R- 가 R-

4.

1 2 , S- 가 S-

5.

1 4 , R CH<sub>3</sub>, CH<sub>3</sub>CH<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, C(CH<sub>3</sub>)<sub>3</sub> C<sub>6</sub>H<sub>5</sub>

6.

1 4 , 가 가

7.

6 , 가 ( *Candida antarctica* ) B, LP 'S',  
( *Pseudomonas* ) , ( *Pseudomonas cepacia* )

8.

7 , 가 B

9.

2 , 가 20% v/v

10.

8 , 30% 50% 가 가

11.

8 , 가 가 70% ee

12.

3 , b) R-

13.

3 ,

a)

S-

b) S-

**14.**

4 , b)

S-

**15.**

4 ,

a)

R-

b) R-

**16.**

1 , b)

R-

**17.**


5% v/v

II

가

가

&lt; II&gt;



, R

**18.**17 , R CH<sub>3</sub>, CH<sub>3</sub>CH<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, C(CH<sub>3</sub>)<sub>3</sub> C  
6 H<sub>5</sub>**19.**

18 , 2,2,2-

가

,

,

, 2,2,2-

, 1-

,

,

,

,

**20.**

19 ,

가

,

,

,

,

**21.**


5% v/v

II

가

가

&lt; II&gt;



, R

**22.**

21 , R CH<sub>3</sub>, CH<sub>3</sub>CH<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, C(CH<sub>3</sub>)<sub>3</sub> C  
6 H<sub>5</sub>

**23.**

22 , 가 1- -2- (PMA), 1- -2-

**24.**

18 22 , 가 가

**25.**

24 , 가 B

**26.**

17 21 , 가 100% v/v

**27.**

26 , 가, 50%

**28.**

17 21 , 30% 50%가

**29.**

17 21 , 가 70% ee

**30.**

17 21 ,

a)

b)

**31.**

17 21 ,

**32.**

17 21 ,

**33.**

a) ( ) ;


b) 1 2 ;

c) 1 2 ;

d) II 1 1 ;

, 2 2 , 1 , 1 , 2

< II >



, R , , - ,

**34.**

33 , 1 1 2 2 100%

**35.**

33 , R CH<sub>3</sub>, CH<sub>3</sub>CH<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>, CH<sub>3</sub>(CH<sub>2</sub>)<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub>, C<sub>6</sub>H<sub>5</sub>, C(CH<sub>3</sub>)<sub>3</sub>, C(CH<sub>3</sub>)<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, C(CH<sub>3</sub>)(C<sub>6</sub>H<sub>5</sub>)<sub>2</sub>, C(C<sub>6</sub>H<sub>5</sub>)<sub>3</sub>, C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, C<sub>6</sub>H<sub>2</sub>CH=CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CH, CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, CH<sub>2</sub>OCH<sub>3</sub>

**36.**

33 , ;

a) 1 ;

b) 1 ;

**37.**

33 , 2

**38.**

33 ,

**39.**

33 ,

a)

;

b) 1 2

**40.**

(a) II , , , , , ;

가

(S)-1- -2-

(R)-1- -2-


(b) (a) (S)-1- -2- ;

(c) (b) (S)-1- -2- ; ( )  
S)-1,2-


(d) (c) (S)-1,2-

III

< III >



&lt; II&gt;



, R , - , , .

**41.**

40 ,

- (e) (b) (R)-1-  
(R)-1,2- -2- ;

- (f) (e) (R)-1,2-

**42.**

40 41 , R C(CH<sub>3</sub>)<sub>3</sub>, C(CH<sub>3</sub>)<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, C(CH<sub>3</sub>)(C<sub>6</sub>H<sub>5</sub>)<sub>2</sub>, C(C<sub>6</sub>H<sub>5</sub>)<sub>3</sub>, C(H<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, CH<sub>2</sub>CH=CH<sub>2</sub>, CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub> CH<sub>2</sub>OC

**43.**42 , R C(CH<sub>3</sub>)<sub>3</sub> .**44.**

40 43 , 가 가

**45.**

44 , 가 가 B

**46.**

40 45 , (c) 가 p-

**47.**

40 ,

- (a) (R,S)-1-tert- -2- (S)-1-tert- -2- (R)-1-tert- - B , - ;

- (b) (S)-1-tert- -2- (R)-1-tert- - ;

- (c) (b) (S)-1-tert- -2- p-  
(S)-1,2- ;

- (d) (c) (S)-1,2-

48.

44

(e) (b)

(R)-1-tert-  
(R)-1,2-

p-


(f) (e) (R)-1,2-

49.


21

가


1




프로필렌 글리콜 메틸 에테르 아세테이트  
PMA  
(1-메톡시-2-프로판올 아세테이트)




프로필렌 글리콜 메틸 에테르  
PM  
(1-메톡시-2-프로판올)




프로필렌 글리콜 에틸 에테르 아세테이트  
PEA




프로필렌 글리콜 에틸 에테르  
PE




프로필렌 글리콜 n-프로필 에테르 아세테이트  
PnPA




프로필렌 글리콜 n-프로필 에테르  
PnP




프로필렌 글리콜 이소프로필 에테르 아세테이트  
PiPA




프로필렌 글리콜 이소프로필 에테르  
PiP




프로필렌 글리콜 n-부틸 에테르 아세테이트  
PnBA



프로필렌 글리콜 n-부틸 에테르  
PnB




프로필렌 글리콜 페닐 에테르 아세테이트  
PPhA




프로필렌 글리콜 페닐 에테르  
PPh


2




3




4A



4B



5



20% PEA의 분할 & 다른 초기량의 카라지암 L-2 C2의 쟈순환  
(주기 시간 = 24h, 단, No. 3 = 48h, No. 8 & 13 = 60h) PEA\_02

